- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07937566
Observational Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma (MCL) in Italian Clinical Practice.
An Observational Cohort Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma (MCL) in Italian Clinical Practice.
Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin lymphoma (B-NHL), characterized by a heterogeneous clinical course and, in a substantial proportion of patients, an aggressive disease behavior requiring timely and effective treatment at diagnosis.
In recent years, the therapeutic landscape of MCL has undergone a major transformation with the introduction of Bruton's tyrosine kinase inhibitors (BTKis). Ibrutinib, acalabrutinib, zanubrutinib, and the non-covalent BTKi pirtobrutinib have demonstrated substantial clinical activity in relapsed/refractry (R/R) MCL. Their role has progressively expanded beyond the relapsed/refractory setting, with BTK inhibitor-based regimens increasingly being incorporated into frontline treatment strategies, supported by emerging clinical trial evidence and reflected in evolving treatment guidelines and clinical practice.
Despite this rapidly evolving treatment landscape, real-world evidence on the use of BTKi-based regimens in the frontline setting remains limited. In particular, data on treatment selection, efficacy, safety, treatment duration, and management of toxicities in routine clinical practice are still scarce.
We therefore propose an observational cohort study to evaluate the clinical impact of previously untreated patients with MCL receiving frontline BTKi-based regimens in routine clinical practice in Italy. The study will assess treatment patterns, effectiveness, safety, and treatment persistence, providing real-world insights into the use of these strategies beyond clinical trials.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Uffici Studi FIL
- Número de teléfono: +390131033153
- Correo electrónico: startup@filinf.it
Copia de seguridad de contactos de estudio
- Nombre: Uffici Studi FIL
- Número de teléfono: +390599769913
- Correo electrónico: gestionestudi@filinf.it
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Previously untreated patients with Mantle Cell Lymphoma receiving frontline Bruton's Tyrosin Kinase-based treatment in routine clinical practice in Italy.
Descripción
Inclusion criteria:
General Inclusion Criteria:
- Histologically confirmed diagnosis of mantle cell lymphoma (MCL) requiring treatment according to current clinical guidelines and standard-of-care recommendations.
- Age ≥ 18 years at the time of BTKi-based treatment initiation.
- Patients who are able to understand the nature and objectives of the study and who have provided written informed consent, approved by the Independent Ethics Committee (IEC), for participation in the observational study.
For the retrospective enrollment group:
In addition to the general inclusion criteria, patients included in the retrospective cohort must meet the following criterion:
● Patients eligible for BTKi-based treatment before the relevant marketing authorization (AIC) in Italy, includingthose treated through off-label use, compassionate use programs, or under Italian Law 648/96, as applicable.
For the prospective enrollment group:
In addition to the general inclusion criteria, patients included in the prospective cohort must meet the following criterion:
● Patients eligible for a BTKi-based regimen in accordance with the EMA-approved indication and the corresponding AIC in Italy.
Exclusion criteria:
- Diagnosis of a histological subtype of lymphoma other than mantle cell lymphoma (MCL).
- Concurrent participation in a prospective interventional clinical trial that may interfere with the assessment of treatment exposure, efficacy, safety, or other study endpoints.
- Inability or unwillingness to provide written informed consent, where required by applicable ethical and regulatory requirements.
- Any condition that, in the investigator's judgment, may preclude reliable collection or interpretation of study data or compromise the patient's ability to participate in the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: CROSS_SECTIONAL
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Retrospective enrollment group
Patients who had an indication for a BTKi-based regimen before the marketing authorization (AIC) in Italy. This group may include patients treated before the relevant AIC through off-label use, compassionate use programs, or treatment provided under Italian Law 648/96. |
|
Prospective enrollment group
Patients eligible for a BTKi-based regimen in accordance with the EMA approved indication and the corresponding AIC in Italy. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Best overall response
Periodo de tiempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined according to Lugano 2014 criteria as the best response recorded between the start of therapy and the end of treatment. Overall response rate (ORR) includes complete (CR) and partial response (PR). Patients without response assessment for any reason are considered non-responders. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Progression-free survival (PFS)
Periodo de tiempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as the time from the start of BTKi-based treatment to the first documentation of relapse, progression or death from any cause. Patients alive without progression are censored at the date of last disease assessment. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Overall survival (OS)
Periodo de tiempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as the time from the start of BTKi-based treatment to death from any cause. Patients alive are censored at the date of last contact. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Event-free survival (EFS)
Periodo de tiempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as the time from the start of BTKi-based treatment to progression, death from any cause or initiation of a new anti-lymphoma treatment (NALT) without documented progression. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Time to next treatment (TTNT)
Periodo de tiempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as the time from the start of BTKi-based treatment to the initiation of a NALT. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Duration of response (DOR)
Periodo de tiempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined in responding patients as the time from the first documentation of CR or PR to progression or death from any cause |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Non-relapse mortality (NRM)
Periodo de tiempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as death without prior relapse or progression |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
POD24
Periodo de tiempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as relapse or progression within 24 months from diagnosis (early POD) or later than 24 months (late POD) |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Incidence of adverse events
Periodo de tiempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Incidence of grade 3, 4 and 5 adverse events according to the latest NCI CTCAE version, and of serious adverse events, occurring after the first dose or at any time during therapy. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Incidence of deaths
Periodo de tiempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Deaths occurring during treatment, at the end of treatment, and during follow-up, with specific assessment of early deaths (defined as deaths occurring within 3 months from treatment initiation), treatment-related (toxic) deaths, and causes of death (any). |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Treatment duration
Periodo de tiempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as the time from the start of BTKi-based treatment to permanent discontinuation for any reason. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Treatment discontinuation
Periodo de tiempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Incidence and reasons for treatment discontinuation (progression, toxicity, death, patient preference, physician decision, planned completion, other). |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Treatment modifications
Periodo de tiempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Frequency and reasons for dose reductions, interruptions and other modifications. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Marco Ladetto, MD, S.C.D.U. Ematologia, I.R.C.C.S. A.O.U. SS. Antonio e Biagio e Cesare Arrigo - Alessandria
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- FIL_MANTLE-FIRST-BTKi
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .